Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes
News Mar 03, 2009
Depomed, Inc. has announced that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program of DM-5689 for the non-hormonal treatment of menopausal hot flashes.
“We are glad that we achieved this milestone today and look forward to the results of both Breeze 1 and Breeze 2 trials in hot flashes expected later this year. We are well on plan in this important execution year for us,” said Carl A. Pelzel, president and chief executive officer of Depomed.
“DM-5689 has the potential to become a significant alternative treatment of hot flashes for the large number of menopausal women in this country. I am glad that we have achieved this milestone in our clinical study today and I would like to convey my thanks to all the Breeze 1 investigators who have made this possible. We look forward to seeing the results later this year,” added Dr. Risa Kagan, of East Bay Physicians Medical Group and Clinical Professor, Dept. Ob/Gyn, UCSF, the lead investigator for the Breeze 1 study.
A new study by investigators from Brigham and Women’s Hospital examined whether pregnancy-related changes may influence how effectively five common AEDs prevent seizures and found that antiepileptic drug clearance significantly changes by the first trimester for the most commonly used medication and by the second trimester for two others.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019